IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background Risk stratification is fundamental in guiding treatment decisions for mRCC patients. The Meet-URO score is a novel prognostic model (IMDC score + NLR + Bone metastases, PMID 36493602) developed in the immunotherapy era. This innovative score enhanced the prognostic discrimination compared with the IMDC score in patients receiving different therapeutic strategies in different settings. Methods A previous external validation on a retrospective real-world cohort of 1174 mRCC patients receiving first-line immune-combinations from 27 centers showed the higher prognostic accuracy of the Meet-URO score compared with the IMDC score (Abstract n. IUC20761-50). Here, we report the updated OS assessment with an exploratory analysis for PFS and ORR. Results: A total of 1,418 patients from 31 cancer centers were assessed: 54% of patients received IO-IO (Nivolumab + Ipilimumab), 46% IO-TKI, mainly Avelumab + Axitinib (24%); 52.5% of patients had NLR ≥ 3.2, and 32% had bone metastases. After an mFU of 16.5 months, the overall mOS was 34.7 months and resulted in more distinction within the Meet-URO score groups (Table 1), confirming its better prognostic accuracy compared with the IMDC score (c-index: 0.68 vs 0.64), especially for intermediate- and poor-risk patients, while for favorable patients, more FU is needed. Although the Meet-URO score was developed as an OS model, it showed better performance also in terms of PFS (c-index: 0.60 vs 0.58) and ORR (c-index: 0.57 vs 0.54). Conclusions The Meet-URO score demonstrated robust and better performance compared with the IMDC score in a large-scale UK mRCC cohort receiving first-line immune-combinations, not only in terms of OS but also in terms of PFS and ORR. The adoption of the Meet-URO score in clinical practice and as a stratification factor of clinical trials could support more individualized patient management.
Source: The Oncologist
Authors: Pasquale Rescigno, Aruni Ghose, Nicholas Brown, Lijo James, Sophia Haywood, Ricky Frazer, Anupama Vijay, Mark Stares, Michael Cheung, Ishika Mahajan, Niall Moon, Ritika Abrol, Ondrej Fiala, Vishwani Chauhan, Yamin Shwe Yee Soe, Anum Zargham, Sara Elena Rebuzzi
Institutions: Newcastle University, Barts Health NHS Trust, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Royal Marsden NHS Foundation Trust, Velindre NHS Trust, Velindre Cancer Centre, University Hospitals of Leicester NHS Trust, NHS Lothian, Cambridge University Hospitals NHS Foundation Trust, United Lincolnshire Hospitals NHS Trust, Royal Cornwall Hospital Trust, Royal Cornwall Hospital, The Royal Wolverhampton NHS Trust, Charles University, Royal Surrey NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Fondazione Ricerca Molinette
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
OpenAlex ID: W4413920814